Turn Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
TTRX$9.92+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in US Dollars)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $10,363,975 | $5,076,144 |
| Prepaid expenses and other current assets | 103,451 | 120,300 |
| Deferred financing cost | 614,070 | - |
| Total current assets | 11,081,496 | 5,196,444 |
| Right-of-use asset | 44,722 | 78,620 |
| Intangible assets, net | 912,673 | 922,171 |
| Deferred offering cost | 4,302,249 | 5,956,424 |
| Security deposit | 8,582 | 8,582 |
| TOTAL ASSETS | $16,349,722 | $12,162,241 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $2,417,544 | $2,928,728 |
| Derivative liability instrument | 570,579 | 3,028,401 |
| Current portion of debt, net of debt discount | 444,204 | - |
| Current portion of operating lease liability | 46,345 | 46,295 |
| Total current liabilities | 3,478,672 | 6,003,424 |
| Operating lease liability, net of current portion | - | 34,081 |
| Long-term debt, net of current portion and debt discount | 5,740,860 | - |
| Deferred revenue | 1,438,013 | 1,438,013 |
| TOTAL LIABILITIES | 10,657,545 | 7,475,518 |
| Commitments and contingencies (Note 11) | ||
| STOCKHOLDERS’ EQUITY | ||
| Common Stock, $0.0001 par value, 500 million Common Stock shares authorized at September 30, 2026 and December 31, 2025; 30,532,704 and 29,445,183 Common Stock shares issued at September 30, 2026 and December 31, 2025, respectively | 3,053 | 2,944 |
| Additional paid-in capital | 41,130,950 | 28,143,872 |
| Subscription receivable | - | (1,070,000) |
| Accumulated deficit | (35,441,826) | (22,390,093) |
| Total stockholders’ equity | 5,692,177 | 4,686,723 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $16,349,722 | $12,162,241 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.